Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sinclair Pharmaceuticals Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner within 1 distinct art unit, representing a very focused and singular prosecution effort. The busiest examiner for this portfolio is MILLER, MAKENNA RYLEIGH, who is responsible for 1 pending office action. This singular focus requires a high degree of precision in responding to the examiner's specific concerns.
Because there is only 1 distinct art unit involved, the technical review is highly concentrated. The presence of only 1 distinct examiner means that the outcome of the prosecution depends entirely on the findings and requirements of this specific individual within the pharmaceutical sector. Practitioners should focus their strategy on the specific preferences of this official, as there are no other pending matters to balance the portfolio's progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MILLER, MAKENNA RYLEIGH | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836815 | COSMETIC PRODUCT CONTAINING STERILE PCL MICROSPHERES | MILLER, MAKENNA RYLEIGH | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836815 | COSMETIC PRODUCT CONTAINING STERILE PCL MICROSPHERES | MILLER, MAKENNA RYLEIGH | 1611 | §103 | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSinclair Pharmaceuticals Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Makenna Ryleigh Miller has the most, with 1 of Sinclair Pharmaceuticals Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
